Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Dysbiosis, Endotoxemia, Metabolic Syndrome, Inflammation
Interventions: Green Tea Extract, Placebo; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions: SNDX-6352, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • The Bronx, New York

Conditions: Septic Shock, Endotoxemia
Interventions: TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock; Device · Other
Lead sponsor: Spectral Diagnostics (US) Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, recombinant interferon alfa; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 5
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more

Conditions: Sepsis, Septic Shock, Emergencies
Interventions: Septic Shock Clinical Decision Support, Clinical Diagnosis Only; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sepsis
Interventions: piperacillin-tazobactam; Drug
Lead sponsor: Phillip Brian Smith; Other
Eligibility: Up to 60 Days
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Indianapolis, Indiana • Wichita, Kansas • Kansas City, Missouri + 1 more

Conditions: Sepsis, Altered Mental Status, Sepsis-Associated Delirium, Sepsis Associated Encephalopathy, Delirium, Sepsis Associated
Interventions: Blood draws; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Aspergillosis, Candidemia
Interventions: anidulafungin and voriconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Sepsis, Relative Adrenal Insufficiency
Interventions: Hydrocortisone Administration (Standard of Care Therapy); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Alcoholic Hepatitis, Sepsis
Interventions: Vitamin C, Dextrose 5% in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Valganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more

Conditions: Systemic Inflammatory Response Syndrome
Interventions: miRNA in Sepsis; Procedure
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Sepsis, Severe Sepsis and Septic Shock
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Severe Sepsis
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Acton, Texas

Conditions: Sepsis
Interventions: Doripenem; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sepsis
Interventions: Continuous Renal Replacement Therapy; Procedure
Lead sponsor: Sunnybrook Health Sciences Centre; Other
Eligibility: 1 Year to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • St. Petersburg, Florida • Atlanta, Georgia + 2 more

Conditions: Sepsis
Interventions: Resatorvid, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more

Conditions: Bacteremia
Interventions: Blood Culture QI Program; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 14,889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: MRSA Infection, Bacteremia, ABSSSI, Pneumonia
Interventions: Not listed
Lead sponsor: CPL Associates; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Neonatal Early-onset Sepsis, Neonatal Late-onset Sepsis
Interventions: Intervention is to stop antibiotics at 24h .; Other
Lead sponsor: Yale University; Other
Eligibility: 1 Hour to 5 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Hemodynamics, Renal Dialysis, Sepsis, Shock
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Viral Infection
Interventions: cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Implementation Trial of Predictive Modeling to Enhance Diagnosis and Improve Treatment in Pediatric Septic Shock

Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates

Sepsis Associated Encephalopathy (SAE) Biomarkers

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

Modulation of Molecular Fingerprinting in Pediatric Sepsis

Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)

Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

Cytokine Removal by CRRT in Pediatric Sepsis

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

Multicenter Blood Culture Quality Improvement

Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline

A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Presep and Vascath Interaction Study

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers